KFAS
VIR icon

Keating Financial Advisory Services’s Vir Biotechnology VIR Stock Holding History

Keating Financial Advisory Services’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67K Hold
164
– – ﹤0.01% 2010
2026
Q1 		$1.47K Buy
+164
New +$1.31K ﹤0.01% 1962

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Keating Financial Advisory Services's VIR Position: Q2 2026 in Review

Keating Financial Advisory Services held its Vir Biotechnology (VIR) position steady in Q2 2026 at 164 shares worth $1.67K. The position accounts for ﹤0.01% of the portfolio, ranked #2010.

Keating Financial Advisory Services first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Keating Financial Advisory Services held 164 shares of Vir Biotechnology worth $1.67K as of Q2 2026.
  • Keating Financial Advisory Services left its Vir Biotechnology share count unchanged in Q2 2026.
  • Vir Biotechnology made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2010 holding.
  • Keating Financial Advisory Services first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.